Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Polaris Group
Information provided by (Responsible Party):
Polaris Group Identifier:
First received: August 8, 2012
Last updated: September 25, 2014
Last verified: September 2014

Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine. In this study, ADI will be combined with the well known chemotherapy cisplatin, and the safety and potential efficacy of this combination will be explored in patients with cancers that require arginine.

Condition Intervention Phase
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Drug: ADI-PEG 20
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies

Resource links provided by NLM:

Further study details as provided by Polaris Group:

Primary Outcome Measures:
  • Number of participants with adverse events. [ Time Frame: Course of study. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of participants with objective responses. [ Time Frame: Course of study. ] [ Designated as safety issue: No ]

Estimated Enrollment: 89
Study Start Date: September 2012
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ADI-PEG 20
arginine deiminase formulated with polyethylene glycol
Drug: ADI-PEG 20
Other Name: arginine deiminase formulated with polyethylene glycol


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed diagnosis of advanced solid tumor (dose escalation component) or metastatic melanoma (uveal or cutaneous) (doses escalation and MTD expansion components) or platinum-resistant (tumor progression within ~ 6 months after the completion of platinum-based therapy) ovarian carcinoma (high-grade serous, endometrial or poorly differentiated endometroid) that is ASS deficient by IHC (defined as <25 % cells ASS positive; see Table 1.4.1 for further details).
  2. Unresectable disease or patient refused surgery.
  3. Progressive disease if treated with chemotherapy, radiotherapy, surgery or immuno-therapy. If prior radiation was given, the measurable disease should be outside the radiation port.
  4. Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).
  5. Age ≥ 18 years.
  6. ECOG performance status of 0 - 1.
  7. No prior systemic therapy, immunotherapy, investigational agent, or radiation therapy within the last 4 weeks.
  8. Fully recovered from any prior surgery and no major surgery within 4 weeks of initiating treatment, except for gamma knife which can take place within 2 weeks. Surgery for placement of vascular access devices is acceptable.
  9. Female subjects and male subjects must be asked to use appropriate contraception for both the male and female for the duration of the study. Subjects must agree to use two forms of contraception or agree to refrain from intercourse for the duration of the study. Females must not be pregnant at the start of the study, and a serum human chorionic gonadotropin (HCG) pregnancy test must be negative before entry into the study. If positive HCG pregnancy test, further evaluation to rule out pregnancy must be performed according to GCP before this patient is claimed eligible.

Exclusion Criteria:

  1. Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment.
  2. Pregnancy or lactation.
  3. Expected non-compliance.
  4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), cardiac arrhythmia, or psychiatric illness, social situations that would limit compliance with study requirements.
  5. Subjects who have had any anticancer treatment prior to entering the study and have not recovered to baseline (except alopecia) or ≤ Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and investigator may be allowed upon agreement with both.
  6. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present in the opinion of the investigator will not affect patient outcome in the setting of current cancer diagnosis.
  7. Subjects who had been treated with ADI-PEG 20 previously.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01665183

Contact: John Bomalaski, MD 858-452-6688 ext 114
Contact: Gisela Peterson, MD, CCRC 858-452-6688 ext 127

United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States
Contact: Siqing Fu, MD    858-452-6688 ext 127      
Principal Investigator: Siqing Fu, MD         
Sponsors and Collaborators
Polaris Group
Principal Investigator: Siqing Fu, MD M.D. Anderson Cancer Center
  More Information

No publications provided

Responsible Party: Polaris Group Identifier: NCT01665183     History of Changes
Other Study ID Numbers: POLARIS2012-005
Study First Received: August 8, 2012
Last Updated: September 25, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Polaris Group:
argininosuccinate synthetase
arginine deiminase

Additional relevant MeSH terms:
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Ovarian Diseases
Urogenital Neoplasms processed this record on October 23, 2014